Bristol-Myers Squibb

Latest Headlines

Latest Headlines

FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin

Bristol-Myers Squibb will go into its Wednesday panel session for the lipodystrophy drug metreleptin with an agency review that offers a grudging concession on signs of efficacy for a subgroup of patients along with some serious questions about potential safety issues and a number of criticisms for the way the clinical trial program was designed and executed.

Bristol-Myers, AstraZeneca get EU nod for diabetes drug

AstraZeneca and Bristol-Myers grabbed a win in the EU today for one of the drugs sprung from their diabetes treatment partnership. But the recommended approval comes even as questions have bubbled up about the future of that relationship.

Bristol-Myers rejigs top management to refocus commercial ops, beef up CFO role

Last week, Bristol-Myers Squibb said it would jettison some research programs, lay off workers and generally reorganize R&D. Now, CEO Lamberto Andreotti is rejigging the commercial side of the business. In the shuffle, current commercial chief Beatrice Cazala will be shunted aside, with current U.S. President Giovanni Caforio taking her place.

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there helped make up for hundreds of millions lost to generic competition. But now, Bristol-Myers says it's getting out of the diabetes discovery business. Will the company back away from its diabetes partnership next?

Bristol-Myers axing up to 75 R&D staffers, halts discovery work in three fields

Bristol-Myers Squibb joined the lineup of biopharma companies executing R&D realignments today, announcing plans to cut back on some of its discovery work in three key disease areas and eliminate 70 to 75 positions in its R&D group as it concentrates resources on late-stage programs.

Bristol-Myers scores first marketing application for all-oral hep C combo

In a notable first, Bristol-Myers Squibb has filed a combination of daclatasvir and asunaprevir for approval to treat hepatitis C in Japan--the first all-oral combo in a regulatory package that excludes interferon.

Bristol-Myers takes shot at Humira as arthritis drug aces Phase IIb

Bristol-Myers Squibb's little-discussed rheumatoid arthritis drug clazakizumab posted strong results in a mid-stage study, meeting its endpoints, notching promising remission data and stirring hopes that the treatment can compete with AbbVie's blockbuster Humira.

UPDATED: Bristol-Myers adds promising survival update on breakthrough cancer drug

Bristol-Myers Squibb has added a few more brushstrokes to the very promising picture that's emerging from early-stage studies of nivolumab, a top PD-1 checkpoint receptor inhibitor billed as a major breakthrough in cancer drug research. 

Ex-Bristol-Myers exec faces 1 year in prison for insider trading

A former Bristol-Myers Squibb executive could have walked out of a courtroom yesterday facing more than three years in prison for insider trading. But he was sentenced to one year and one day behind bars after pleading guilty to profiting off private information about Bristol-Myers M&A action.

Bristol-Myers exec sentenced to a year in prison on insider trading scheme

When Bristol-Myers Squibb wanted to take over a company, execs turns to Robert Ramnarine in their Princeton, NJ, office to do the confidential due diligence work on the target company's pension plan.